JP4527979B2 - 癌を治療する方法 - Google Patents

癌を治療する方法 Download PDF

Info

Publication number
JP4527979B2
JP4527979B2 JP2003550718A JP2003550718A JP4527979B2 JP 4527979 B2 JP4527979 B2 JP 4527979B2 JP 2003550718 A JP2003550718 A JP 2003550718A JP 2003550718 A JP2003550718 A JP 2003550718A JP 4527979 B2 JP4527979 B2 JP 4527979B2
Authority
JP
Japan
Prior art keywords
use according
mycobacterium
pharmaceutical composition
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003550718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528332A5 (enExample
JP2005528332A (ja
Inventor
カーマー，バクレシュ，マファトラル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005528332A publication Critical patent/JP2005528332A/ja
Publication of JP2005528332A5 publication Critical patent/JP2005528332A5/ja
Application granted granted Critical
Publication of JP4527979B2 publication Critical patent/JP4527979B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003550718A 2001-12-10 2002-12-10 癌を治療する方法 Expired - Fee Related JP4527979B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1167MU2001 2001-12-10
PCT/IB2002/005516 WO2003049667A2 (en) 2001-12-10 2002-12-10 The method of treating cancer

Publications (3)

Publication Number Publication Date
JP2005528332A JP2005528332A (ja) 2005-09-22
JP2005528332A5 JP2005528332A5 (enExample) 2006-01-05
JP4527979B2 true JP4527979B2 (ja) 2010-08-18

Family

ID=11097334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550718A Expired - Fee Related JP4527979B2 (ja) 2001-12-10 2002-12-10 癌を治療する方法

Country Status (9)

Country Link
US (1) US7972609B2 (enExample)
JP (1) JP4527979B2 (enExample)
AP (1) AP1896A (enExample)
AU (1) AU2002348738B2 (enExample)
CA (1) CA2469266C (enExample)
GB (1) GB2389532C (enExample)
NZ (1) NZ533417A (enExample)
UA (1) UA79952C2 (enExample)
WO (1) WO2003049667A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632353C (en) 2005-04-25 2018-02-20 Bakulesh Mafatlal Khamar Vaccine adjuvants comprising mycobaterium
AU2007323134B2 (en) * 2006-11-23 2013-05-02 Cadila Pharmaceuticals Limited Poly-TLR antagonist
CA2681420A1 (en) * 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
AU2008269427A1 (en) * 2007-06-28 2008-12-31 Cadila Pharmaceuticals Ltd. Mitogen activated protein kinase modulator
WO2011083493A1 (en) * 2010-01-08 2011-07-14 National Institute Of Immunology Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer
CN102753975B (zh) * 2010-02-19 2015-05-20 卡帝拉药物有限公司 基本上保留免疫原性的被杀死细胞的药物组合物
WO2012049654A1 (en) * 2010-10-13 2012-04-19 Bioniche Life Sciences, Inc. Bacterial ribonucleic acid cell wall compositions and methods of making and using them
PL2663318T3 (pl) * 2011-01-11 2015-08-31 Cadila Pharmaceuticals Ltd Kompozycja farmaceutyczna do leczenia raka
TR201101874A2 (tr) * 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.
CA2828401C (en) * 2011-02-28 2023-01-10 Cadila Pharmaceuticals Limited Therapeutic cancer vaccine
ES2647768T3 (es) * 2011-07-05 2017-12-26 Cadila Pharmaceuticals Limited Antígeno de cáncer
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5767156A (en) 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US6090385A (en) 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6056964A (en) 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5869645A (en) 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
BR0303367A (pt) * 2002-03-08 2004-07-20 Bakulesh Mafatlal Khamar Células de mycobacterium w, veìculo farmaceuticamente aceitável, preservativo, ruptura de mycobacterium w, extração de solvente, enzimas usadas para a extração enzimática de células de mycobacterium w, adjuvante, composição farmacêutica, tensoativo, e, concentração de tensoativo do processo de fabricar uma composição farmacêutica para a administração de tuberculose

Also Published As

Publication number Publication date
AU2002348738A1 (en) 2003-06-23
CA2469266C (en) 2014-02-11
UA79952C2 (en) 2007-08-10
CA2469266A1 (en) 2003-06-19
AP1896A (en) 2008-10-08
WO2003049667A2 (en) 2003-06-19
GB2389532A (en) 2003-12-17
US20070259005A1 (en) 2007-11-08
US7972609B2 (en) 2011-07-05
GB0322773D0 (en) 2003-10-29
NZ533417A (en) 2008-04-30
AP2004003070A0 (en) 2004-06-30
GB2389532B (en) 2004-10-27
JP2005528332A (ja) 2005-09-22
AU2002348738B2 (en) 2007-11-08
WO2003049667A3 (en) 2003-10-09
GB2389532C (en) 2005-09-08

Similar Documents

Publication Publication Date Title
CA1333152C (en) Vaccine containing tumor antigens and adjuvants
Zhu et al. Innovative applications of bacteria and their derivatives in targeted tumor therapy
JP2022538765A5 (enExample)
Skinner et al. Vaccination of animals against Mycobacterium bovis
JP4135190B2 (ja) 免疫治療剤とその使用
Lee et al. T cell augments the antitumor activity of tumor-targeting Salmonella
US7972609B2 (en) Method of treating cancer
WO2003049751A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
US9056073B2 (en) Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
US20120014985A1 (en) Vaccine Adjuvants
Steenken Jr et al. Vaccinating properties of avirulent dissociates of five different strains of tubercle bacilli
WO2010031883A1 (es) Agente inmunoterapéutico apropiado para la profilaxis primaria de la tuberculosis
JP2005519941A (ja) 結核の管理のために有用な医薬組成物の製造方法
CN119679933A (zh) 一种基于akk菌的肿瘤疫苗及其制备方法和应用
Julián et al. Bacteria-derived alternatives to live Mycobacterium bovis Bacillus Calmette-Guerin for nonmuscle invasive bladder cancer treatment
CN107073106A (zh) 用于治疗泌尿生殖系统癌症的减毒或失活病原性大肠杆菌
EP0969851B1 (fr) Complexe immunomodulateur et son utilisation dans les affections par helicobacter
JP2006502090A (ja) Ｈｉｖ陽性の個体で予防を結核に提供している方法
WO2003075825A2 (en) The method of treating tuberculosis
JPS63174933A (ja) 抗腫瘍剤
HK1138786A1 (en) Prophylactic tuberculosis vaccine
AU2003202725A1 (en) Method of providing prophylaxis for tuberculosis in HIV positive individuals
HK1138786B (en) Prophylactic tuberculosis vaccine
MXPA96004401A (es) Agente inmunoterapeutico y su uso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091211

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100518

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100604

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130611

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4527979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees